Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Modalis Therapeutics hits year-high on potent gene suppression in MD candidates
Modalis Therapeutics to Present New Preclinical Data Demonstrating Robust Gene Suppression for MDL-202 and MDL-103 at ASGCT 2026
Notice Regarding the Transfer of Fixed Assets at the US Subsidiary and the Recognition of Extraordinary Income
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
Notice Regarding Issuance of Stock Options (Share Acquisition Rights)
Business Plans and Matters Related to High Growth Potential
Modalis Therapeutics to Present Latest Preclinical Data and Clinical Trial Plans for MDL-101 at the 2026 LAMA2 Conference
Notice regarding partial amendment of the Articles of Incorporation
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
Modalis Therapeutics, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
Strategic Development Progress Update for MDL-101: Clinical Readiness Advancement and Program Optimization
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
2025 Fiscal Year End Business and Financial report
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [Japanese GAAP]
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Financial Results for the Nine Months Ended September 30, 2025
Modalis Therapeutics, Jan-Sep (Cumulative 3Q) Net Income Loss Widens, Jul-Sep Net Income Loss Widens
Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP]